Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
CancerClinical Trial

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1577563

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1577563

Mycosis Fungoides Therapeutics

PUBLISHED:
PAGES: 182 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Mycosis Fungoides Therapeutics Market to Reach US$587.2 Million by 2030

The global market for Mycosis Fungoides Therapeutics estimated at US$467.3 Million in the year 2023, is expected to reach US$587.2 Million by 2030, growing at a CAGR of 3.3% over the analysis period 2023-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$371.1 Million by the end of the analysis period. Growth in the Biologic Drugs segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$127.3 Million While China is Forecast to Grow at 6.4% CAGR

The Mycosis Fungoides Therapeutics market in the U.S. is estimated at US$127.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$121.2 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Mycosis Fungoides Therapeutics Market - Key Trends and Drivers Summarized

What Is Mycosis Fungoides and Why Is Effective Therapeutic Management Crucial?

Mycosis Fungoides is the most common type of cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer of the lymphocytes that primarily affects the skin. The disease is characterized by malignant T-cells infiltrating the skin, leading to patchy rashes, plaques, and in more severe stages, tumors and systemic involvement. Effective therapeutic management is critical because Mycosis Fungoides is a progressive disease that can evolve over several years, transitioning from early, less aggressive stages to more advanced stages where the disease can significantly impact the patient’s quality of life and overall survival. Although it is typically an indolent condition, its variable presentation and potential to transform into aggressive variants, such as Sézary syndrome, necessitate a comprehensive therapeutic approach that considers both skin-directed and systemic treatments. Managing this disease is complex due to its heterogeneity, with some patients remaining stable for decades while others experience rapid disease progression. As a result, there is no one-size-fits-all treatment, and the therapeutic strategy must be tailored to each individual, depending on the disease stage, severity of symptoms, and patient comorbidities. Given the complexity of Mycosis Fungoides, research into more effective, less invasive therapies continues to be of paramount importance to improve patient outcomes and provide long-term disease control.

What Are the Current Therapeutic Approaches and Limitations in Treating Mycosis Fungoides?

The treatment landscape for Mycosis Fungoides is diverse, encompassing a range of modalities that include topical therapies, systemic drugs, and newer biologics, depending on the stage and presentation of the disease. In early-stage Mycosis Fungoides, skin-directed therapies such as corticosteroids, topical chemotherapy agents (e.g., mechlorethamine), and retinoids (e.g., bexarotene) are commonly used to manage localized skin lesions and alleviate symptoms. Phototherapy, particularly narrowband ultraviolet B (NB-UVB) and psoralen plus ultraviolet A (PUVA), has shown to be effective in achieving remission in early-stage patients. For more advanced cases, systemic therapies, including interferons, histone deacetylase (HDAC) inhibitors like vorinostat, and monoclonal antibodies like mogamulizumab, are utilized to target widespread disease and systemic involvement. Despite the availability of these therapeutic options, Mycosis Fungoides remains a challenging condition to treat due to its relapsing nature and the potential for resistance to therapies over time. The limitations of current therapies, such as treatment-related side effects, risk of secondary cancers with long-term phototherapy, and limited efficacy in advanced stages, underscore the need for novel treatments that can provide better control with fewer adverse effects. As a result, the search for new therapies that target the underlying molecular and immune mechanisms of the disease is ongoing, with emerging treatments aiming to improve response rates, delay disease progression, and enhance patient quality of life.

How Are Technological and Scientific Innovations Changing the Mycosis Fungoides Therapeutics Landscape?

Recent advancements in molecular biology and immunotherapy are transforming the therapeutic landscape for Mycosis Fungoides, providing new avenues for more targeted and effective treatments. One of the most promising areas of development is the use of biologics, which are engineered to specifically target malignant T-cells. Mogamulizumab, a monoclonal antibody targeting the CCR4 receptor, has shown significant efficacy in reducing tumor burden and providing symptom relief in patients with refractory Mycosis Fungoides. Other biologics and small molecules targeting key pathways involved in T-cell survival and proliferation, such as the JAK-STAT and PI3K pathways, are also in various stages of clinical development. Additionally, checkpoint inhibitors, which modulate the immune system’s response to cancer cells, are being explored for their potential to treat aggressive forms of CTCL. The advent of precision medicine, which utilizes genetic and molecular profiling to tailor therapies to the individual’s unique disease characteristics, is another breakthrough that could revolutionize treatment. Identifying specific biomarkers that predict response to therapy could help refine treatment strategies and minimize unnecessary exposure to ineffective drugs. Furthermore, advanced imaging technologies, such as high-definition PET/CT scans, are improving disease monitoring, allowing clinicians to detect early signs of progression and adjust treatment plans accordingly. These innovations are not only expanding the therapeutic options for Mycosis Fungoides but are also paving the way for a more personalized, patient-centered approach to care.

What Factors Are Driving the Growth of the Mycosis Fungoides Therapeutics Market?

The growth in the Mycosis Fungoides therapeutics market is driven by several factors, primarily influenced by advancements in treatment technologies, evolving clinical practices, and changing patient demographics. One of the main drivers is the increasing prevalence of Mycosis Fungoides and other cutaneous lymphomas, particularly in the aging population, which is more susceptible to these conditions. The rise in the elderly population is significantly expanding the patient pool, driving the demand for effective and tolerable treatment options. Additionally, the growing focus on early diagnosis and the increased adoption of sophisticated diagnostic tools are leading to more patients being identified at earlier stages, thereby increasing the need for early-stage therapeutic interventions. Another key factor is the surge in research and development activities, with several pharmaceutical companies investing heavily in novel biologics and targeted therapies to address the unmet needs in advanced Mycosis Fungoides. The ongoing shift towards personalized medicine is further boosting market growth, as clinicians and researchers strive to match treatments with specific disease profiles. The increasing use of telemedicine and digital health platforms for monitoring and managing chronic conditions like Mycosis Fungoides is also contributing to market expansion, as these technologies enhance patient engagement and enable more effective long-term disease management. Furthermore, favorable regulatory frameworks, including orphan drug designations and expedited approval pathways for rare disease therapies, are incentivizing the development and commercialization of innovative therapeutics. Collectively, these factors are shaping the future of the Mycosis Fungoides therapeutics market, making it a dynamic and rapidly evolving segment within the broader oncology and dermatology space.

Select Competitors (Total 44 Featured) -

  • 4SC
  • BioInvent International AB
  • Bristol-Myers Squibb Company
  • Cartherics Pty Ltd.
  • Citius Pharmaceuticals, Inc.
  • CRISPR Therapeutics
  • Helsinn Healthcare SA
  • Innate Pharma SA
  • Kite Pharma, Inc.
  • Kyowa Kirin Co., Ltd.
Show more
Product Code: MCP24281

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Mycosis Fungoides Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Mycosis Fungoides Drives Demand for Advanced Therapeutic Solutions
    • Here's the Story: How Growing Awareness and Early Diagnosis Expand the Addressable Market for Mycosis Fungoides Treatments
    • Increasing Focus on Targeted Therapies Propels Market Growth for Novel Drug Developments
    • Advancements in Immunotherapy and Monoclonal Antibodies Generate New Opportunities for Mycosis Fungoides Management
    • Here's How Personalized Medicine Approaches Strengthen the Business Case for Patient-Specific Treatment Protocols
    • Rising Adoption of Combination Therapies Spurs Demand for Multifaceted Treatment Regimens
    • Growing Focus on Minimally Invasive Treatment Options Drives Adoption of Topical and Skin-Directed Therapies
    • Growing Demand for Non-Chemotherapeutic Options Spurs Innovation in Biologic and Immune-Based Therapies
    • Rising Healthcare Expenditure in Emerging Markets Expands Market Scope for Mycosis Fungoides Therapeutics
    • Increasing Use of Digital Health Platforms Transforms Market Dynamics through Enhanced Patient Monitoring
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mycosis Fungoides Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Small Molecule Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Small Molecule Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biologic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biologic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Biologic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • JAPAN
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • CHINA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: China 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • EUROPE
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • FRANCE
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: France 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • GERMANY
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • INDIA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: India 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Mycosis Fungoides Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Mycosis Fungoides Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030
  • AFRICA
    • Mycosis Fungoides Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Mycosis Fungoides Therapeutics by Drug Type - Small Molecule Drugs and Biologic Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Mycosis Fungoides Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Small Molecule Drugs and Biologic Drugs for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!